Market Intelligence, Clinical Progress, and High-Purity Reagents for Skeletal Muscle Channelopathy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CACNA1S-targeted drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CACNA1S Extracellular Domain & Loop Peptides; high purity (>95%), Endotoxin <1 EU/ug, Sequence Verified. | View CACNA1S Products |
| Gene Delivery | CACNA1S Full-Length ORF Lentivirus Premade Particles; high titer (>10⁸ TU/ml), Puromycin/Blasticidin selectable, Sequence Verified by NGS. | View CACNA1S Products |
| Stable Cell Line | CACNA1S HEK293 stable cell line co-expressed with CACNB1 auxiliary subunit; native glycosylation, endotoxin controlled, compatible with patch-clamp. | View CACNA1S Products |
| Benchmark Antibody | Anti-CACNA1S recombinant monoclonal antibody (extracellular loop domain); Sequence Verified, suitable for FACS, immunofluorescence, and western blot. | View CACNA1S Products |
| Validator | CACNA1S siRNA Set (3 unique sequences); for knockdown verification and specificity controls in cell-based assays. | View CACNA1S Products |
| Selectivity Panel | CACNA1C (Cav1.2) Lentivirus / Stable Cell Line; cardiac homolog for cross-reactivity and off-target counter-screening. | View CACNA1C Products |
| Pathway Partner | RYR1 (Ryanodine Receptor 1) recombinant protein; direct functional partner in excitation-contraction coupling. | View RYR1 Products |
| Auxiliary Subunit | CACNB1 (Calcium Channel Beta Subunit); required for CACNA1S membrane trafficking and gating. Co-expression systems with CACNA2D1 or CACNG1 also available. | View CACNB1 Products |
| Essential Accessory | STAC3 (SH3 And Cysteine Rich Domain 3); essential for Cav1.1 surface expression and voltage-sensing coupling to RYR1. | View STAC3 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving 24-transmembrane folding & native gating behavior | Full-length Lentivirus premade particles sequence-verified by NGS for stable HEK293/CHO cell line construction; preserves native topology and glycosylation. |
| Skeletal vs cardiac selectivity (Cav1.1 vs Cav1.2) | Homolog panel expression constructs (CACNA1C, CACNA1D) with strictly verified sequences for electrophysiological counter-screening; species-matched orthologs (human/mouse/cyno) available. |
| State-dependent drug binding (resting vs inactivated) | Stable cell lines compatible with automated patch-clamp (APC) and voltage-clamp protocols; high-expression clones enable sufficient current density for pharmacology. |
| Auxiliary subunit dependency | Co-expression systems with CACNB1, CACNA2D1, or CACNG1 to replicate native channel complexes; multi-gene lentivirus available. |
| Mutant disease modeling (HypoPP / MHS) | Custom disease-mutant ORF Lentivirus constructs (e.g., R528H, R1239H, R1086H) for modeling gating pore currents (omega currents). |
| Assay specificity & false positives | Validated siRNA sets included for background subtraction and specificity checks; high-purity benchmark antibodies and recombinant positive controls. |
Live CACNA1S R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
CACNA1S encodes the pore-forming α1-subunit of the skeletal muscle L-type calcium channel (Cav1.1/DHPR), the primary voltage sensor for excitation-contraction coupling. Pathogenic mutations cause hypokalemic periodic paralysis (HypoPP), malignant hyperthermia susceptibility (MHS), and rare forms of congenital myopathy.
The R&D landscape is shifting from non-selective broad-spectrum calcium channel blockers (e.g., dihydropyridines) toward precision allosteric modulators, antisense oligonucleotides (ASOs), and viral-mediated gene correction. Traditional L-type antagonists lack sufficient selectivity over the cardiac paralog Cav1.2, leading to dose-limiting cardiovascular toxicity. Current focus areas include:
- State-dependent small molecule modulators: Targeting the inactivated state of Cav1.1 to reduce skeletal muscle excitability without cardiac side effects. Key goal: >100-fold selectivity over Cav1.2/Cav1.3.
- ASO / siRNA therapies: For MHS prophylaxis and dominant-negative HypoPP alleles, entering preclinical stages.
- Gene therapy (AAV/Lentiviral): For congenital myopathies and channelopathies, using muscle-specific promoters.
- Gating pore current (omega current) specific blockers: For HypoPP patients with mutations (R528H, R1239H) that create aberrant leak currents; the next frontier is selective inhibition of gating pore currents without affecting central pore excitation-contraction coupling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (State-Dependent Blockers) | Academic & Rare Disease Biotechs | Hypokalemic Periodic Paralysis (HypoPP), Malignant Hyperthermia | Subtype selectivity electrophysiology assay (full-length cell lines vs Cav1.2); state-dependent patch-clamp protocols. |
| ASO / siRNA | Gene Therapy & RNA Innovators (e.g., Ionis) | Malignant Hyperthermia Susceptibility (MHS), HypoPP | Knockdown & splicing validation assay (sequence-verified siRNA sets and disease-mutant ORF models). |
| Gene Therapy (AAV/Lentiviral) | Neuromuscular Biopharma | Congenital Myopathies, Channelopathies | Functional rescue & surface expression assay (high-purity benchmark antibodies and native expression controls). |
| Biologic (mAb/ScFv) | Emerging Biotechs | Skeletal Muscle Disorders | Extracellular domain mapping tools; FACS-compatible cell surface expression systems. |
Molecular Differentiation & Assay Strategy
1. Subtype Selectivity (Skeletal vs Cardiac)
- Need: Distinguish Cav1.1 from Cav1.2 (CACNA1C) and Cav1.3 (CACNA1D); sequence homology ~70%. Therapeutic window requires >100-fold selectivity.
- Assay: Parallel cell line panel (CACNA1S, CACNA1C, CACNA1D) for patch-clamp and FLIPR calcium flux assays. TarMart provides human/mouse/cyno ortholog panels.
2. State-Dependent Binding (Resting vs Inactivated)
- Need: HypoPP treatment requires preferential block of inactivated state to reduce abnormal depolarization; resting-state block leads to muscle weakness.
- Assay: Voltage-clamp protocols with holding potentials capturing resting and inactivated states. Requires stable cell lines with high current density (>200 pA/pF). TarMart's high-titer lentivirus ensures >90% transduction efficiency and uniform high expression.
3. Auxiliary Subunit Dependence
- Need: Native Cav1.1 forms a complex with β1a (CACNB1), α2-δ, and γ1 subunits; drug binding may involve subunit interfaces.
- Assay: Co-expression systems (CACNA1S + CACNB1 + CACNA2D1) to compare pharmacology with α1 alone. TarMart offers multi-gene lentivirus systems with controlled stoichiometry.
4. Mutant Validation (Disease-Specific)
- Need: Mutations such as R528H (voltage-sensor domain) and R1239H (pore domain) alter gating and create gating pore currents. Drugs must be tested on mutant channels.
- Assay: Disease-in-a-dish model using stable cell lines expressing mutant CACNA1S. TarMart provides site-directed mutagenesis-verified ORF clones (R528H, R1239H, R1086H) with Sanger sequencing validation.
Related Targets for Cross-Selling
- RYR1 (Ryanodine Receptor 1): Direct mechanical coupling partner; mutations frequently co-occur in MHS and core myopathies.
- CACNA1C (Cav1.2): Cardiac L-type calcium channel; mandatory counter-screen for cardiovascular safety.
- CACNB1 (Calcium Channel Beta Subunit): Essential for membrane trafficking and gating; co-expression required for physiologically relevant assays.
- STAC3 (SH3 and Cysteine Rich Domain 3): Necessary for Cav1.1 surface expression and voltage-sensing coupling to RYR1; crucial for functional electrophysiological recordings in heterologous systems.
- SCN4A (Nav1.4): Skeletal muscle sodium channel; co-dysregulation in HypoPP; potential combination therapy target.